Cancer Conversations on the Expanding Therapeutic Landscape for CDK4/6 Inhibitors in HR-Positive/HER2-Negative Breast Cancer

Learn more about the evolving role of CDK4/6 inhibitors to treat patients with HR-positive/HER2-negative breast cancer through a certified on-demand webcast, downloadable self-teaching slideset, and podcast.

Share

Program Content

Activities

CDK4_6 Inhibitors in HR+, HER2-Negative Breast Cancer
Cancer Conversations on the Expanding Therapeutic Landscape for CDK4/6 Inhibitors in HR-Positive/HER2-Negative Breast Cancer
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: May 30, 2024

Expires: May 29, 2025

Inhibiteurs de CDK4/6 cancer du sein HR+/HER2-
Conversations autour du cancer portant sur l'élargissement du paysage thérapeutique des inhibiteurs de CDK4/6 dans le traitement du cancer du sein HR+/HER2-
PDF
Congratulations: You achieved a completion on 04/09/2022

Released: July 26, 2024

Expires: July 25, 2025

Inibidores de CDK4/6 em câncer de mama HR+/HER2-
Conversas sobre o câncer: o cenário terapêutico em expansão para inibidores de CDK4/6 em câncer de mama HR-positivo/HER2-negativo
PDF
Congratulations: You achieved a completion on 04/09/2022

Released: August 19, 2024

Expires: August 18, 2025

Los inhibidores de CDK4/6 en el cáncer de mama RH+/HER2-
Conversaciones sobre el cáncer de mama RH positivo/HER2 negativo en el panorama terapéutico en expansión de los inhibidores de CDK4/6
PDF
Congratulations: You achieved a completion on 04/09/2022

Released: August 21, 2024

Expires: August 20, 2025

Activities

HR Positive HER2 Negative Breast Cancer at ASCO 2024
Cancer Conversations on the Expanding Therapeutic Landscape for CDK4/6 Inhibitors in HR-Positive/HER2-Negative Breast Cancer
Video
Congratulations: You achieved a completion on 04/09/2022

Released: June 17, 2024

Expires: June 16, 2025

Activities

CDK4,6 Inhibition in Breast Cancer
Experts Discuss the Role of CDK4/6 Inhibitors in HR+/HER2- Breast Cancer
Podcast Episodes
Congratulations: You achieved a completion on 04/09/2022

Released: July 09, 2024

Expires: July 08, 2025

Activities

CDK4,6 Inhibitors in Breast Cancer
Experts Answer Your Questions on CDK4/6 Inhibitors in HR+/HER2- Breast Cancer
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: July 05, 2024

Expires: July 04, 2025

Inhibiteurs de CDK4/6 dans le cancer du sein HR+/HER2-
Des experts répondent à vos questions concernant les inhibiteurs de CDK4/6 dans le cancer du sein HR+/HER2-
PDF
Congratulations: You achieved a completion on 04/09/2022

Released: August 09, 2024

Expires: August 08, 2025

Inibidores de CDK4/6 no câncer de mama HR+/HER2-
Especialistas respondem às suas perguntas sobre inibidores de CDK4/6 no câncer de mama HR+/HER2-
PDF
Congratulations: You achieved a completion on 04/09/2022

Released: August 19, 2024

Expires: August 18, 2025

Los inhibidores de CDK4/6 en el cáncer de mama RH+/HER2-
Los expertos responden a sus preguntas sobre los inhibidores de CDK4/6 en el cáncer de mama RH+/HER2-
PDF
Congratulations: You achieved a completion on 04/09/2022

Released: August 21, 2024

Expires: August 20, 2025

Faculty

cover img faculity

Sara A. Hurvitz, MD, FACP

Professor of Medicine
Head, Division of Hematology and Oncology
Department of Medicine, UW Medicine
Senior Vice President
Clinical Research Division
Fred Hutchinson Cancer Center
Seattle, Washington

cover img faculity

Erica L. Mayer, MD, MPH

Director of Breast Cancer Clinical Research
Institute Physician
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

cover img faculity

Joyce O'Shaughnessy, MD

Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Chair, Breast Disease Committee
Sarah Cannon Research Institute
Texas Oncology
Dallas, Texas

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

Supported by educational grants from Lilly and Novartis Pharmaceuticals Corporation.

Lilly

Novartis Pharmaceuticals Corporation